Jun Xu

US Patent:

6504008, Jan 7, 2003

Filed:

Feb 1, 1999

Appl. No.:

09/241888

Inventors:

Jun Xu - Ossining NY
Joshua Trueheart - South Nyack NY

Assignee:

Cadus Technologies, Inc. - New York NY

International Classification:

C07K 1400

US Classification:

530350, 530371

Abstract:

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e. g. , a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay of the invention makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e. g. , when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell. Thus, the cell provides a signal generation means comprising a novel fusion protein the expression of which is independent of stimulation/activation of the signal transduction pathway, but the activity of which is responsive to the signal transduction pathway.

US Patent:

7022513, Apr 4, 2006

Filed:

Jul 18, 2002

Appl. No.:

10/200013

Inventors:

Jun Xu - Ossining NY, US
Joshua Trueheart - South Nyack NY, US

Assignee:

Cadus Technologies, Inc. - New York NY

International Classification:

C12N 1/16

US Classification:

4352551, 435243, 4352541, 43525411, 4352542, 43525421, 4352552

Abstract:

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e. g. , a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay of the invention makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e. g. , when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell. Thus, the cell provides a signal generation means comprising a novel fusion protein the expression of which is independent of stimulation/activation of the signal transduction pathway, but the activity of which is responsive to the signal transduction pathway.

US Patent:

20210392097, Dec 16, 2021

Filed:

Feb 23, 2021

Appl. No.:

17/249191

Inventors:

- Santa Monica CA, US
John Jensen - Santa Monica CA, US
Michel Khristo - Santa Monica CA, US
Sivakumar Loganathan - San Francisco CA, US
Patrick Mandia - Venice CA, US
Jun Xu - Marina del Rey CA, US
Austin Yeakel - Santa Monica CA, US

International Classification:

H04L 12/58
H04L 29/08

Abstract:

A bidirectional bridge for web view is a technical solution to an engineering challenge associated with presenting external content in a web view. A bidirectional bridge for web view facilitates bidirectional communication between the web view included in the messaging client and the messaging client itself. In response to a user action requesting a web page to be loaded in the web view, the bidirectional bridge initiates a request to messaging client to retrieve external content, receives the requested external content from the messaging client, and displays an image representing the external content in the web view as part of the web page.